Nutritional aspects of metabolic bone disease in the newborn

Steven Ryan

Metabolic bone disease (MBD) in the newborn predominantly affects preterm neonates, although there are a few reports of babies with congenital rickets after maternal vitamin D deficiency. Features of MBD in preterm neonates include radiological abnormalities such as fractures, rickets, and osteoporosis; biochemical features such as raised blood alkaline phosphatase activity or hypophosphataemia; skeletal deformity such as rib cage softening and altered head shape; and diminished linear growth velocity.

MBD can arise from insufficient dietary minerals (calcium and or phosphorus), too little collagen, or abnormal collagen.

MBD mainly arises from dietary mineral deficiency in the newborn, although copper deficiency, as a result of abnormal collagen metabolism, has also been implicated. It is difficult to differentiate these two processes, because they often occur in the same patient.

The pathology of MBD in preterm neonates shows generalised skeletal mineralisation, a reduction in the amount of osseous tissue (osteoporosis), and a disordered metaphyseal cartilage plate similar to that seen in classic rickets.

Using formal balance studies, other groups showed rates of calcium and phosphorus retention equivalent to those seen in utero, with milk contents of calcium (31 to 37.5 mmol/l) and phosphorus (21 to 27 mmol/l). These studies were the basis for the concentrations of calcium and phosphorus found in current preterm cow’s milk formulas used in the United States. Levels in European formulas tend to be somewhat lower.

The hypothesis that the dietary mineral deficit relative to the in utero experience is responsible for MBD and bone mineral deficiency is based on calcium requirements. Calcium deficiency is very rare and has been described only after the accidental omission of calcium from parenteral nutrition solutions. Phosphorus deficiency has a more direct association with overt MBD and this is felt to be because phosphorus and calcium are taken up differentially by the skeleton and other tissues. Ninety eight per cent of body calcium is located in bone mineral compared with 85% of phosphorus; the other 15% resides in other tissues. Consequently, at very low mineral intakes, phosphorus deficiency arises first, as the lean tissues take priority, leaving little for the skeleton.

Phosphorus deficiency is seen in preterm neonates who are fed unfortified human milk,7 and during parenteral nutrition,8 when phosphorus intake may be as low as 0.5 mmol/kg/day, compared with the in utero requirement of 2-1 to 2-6 mmol/kg/day. Features of phosphorus deficiency are low blood phosphorus concentration (<1.2 mmol/l), high tubular reabsorption of phosphorus (>95%), and evidence of excess calcium in urine.7 Forty two per cent of human milk fed preterm neonates develop radiological evidence of rickets,9 associated with lower plasma phosphorus concentrations than seen in those without overt bone disease. Some degree of phosphorus deficiency seems to arise antenatally and is related to placental abnormality.9 This fits in with the association of a number of adverse antenatal factors with MBD of prematurity.10 MBD defined by plasma alkaline phosphatase activity of >1200 IU/l occurs in 25% of neonates receiving unfortified pooled donor breast milk compared with 14% receiving a preterm formula.11

**Nutritional aetiology of MBD in preterm neonates**

**MINERAL DEFICIENCY**

In 1980 Steichen, Gratton, and Tsang directly examined the effect of dietary mineral enhancement on bone mineralisation. Having contrasted the exponential requirement for calcium in utero (between 3.25 and 3.9 mmol/kg/day) with the usual estimated postnatal dietary calcium retentions (between 1.6 and 2.5 mmol/kg/day), they supplemented formula milk with calcium (41.5 mmol/l) and phosphorus (20 mmol/l) and were able to show, using photon absorptiometry, peripheral skeletal bone mineral accretion equivalent to that in utero. Without dietary mineral enhancement, bone mineral accretion is negligible. In effect Steichen et al were mimicking the increase in total body calcium content from 5 g at 26 weeks of gestation, to 30 g at full term. The results of this small study have not been replicated by others, possibly because the control group had a lower bone mineral content before supplementation was started.
VITAMIN D DEFICIENCY

At one time vitamin D deficiency was felt to be the main cause of MBD in preterm neonates. This assumption had quite naturally arisen because of the similarity of rachitic changes in preterm neonates with those in older children with nutritional vitamin D deficiency. In fact, preterm neonates have increased concentrations of 1,25 dihydroxyvitamin D, the active hormone, which increase with age. In preterm infants with overt MBD, 1,25 dihydroxyvitamin D concentrations are even higher and fall with mineral supplementation. This suggests that the raised concentration of the hormone is a response to dietary mineral insufficiency.

A previous study suggested that a daily vitamin D intake of 1000 IU is adequate, although daily doses as low as 400 IU are probably adequate in otherwise healthy preterm neonates. End organ (gut) unresponsiveness to 1,25 dihydroxyvitamin D has been postulated in preterm neonates, and is supported by an apparent lack of any association between vitamin D intake and calcium absorption, but has not been confirmed.

COPPER DEFICIENCY

The bone abnormalities of copper deficiency are indistinguishable from those seen in MBD because of bone mineral deficiency in preterm neonates. Additional bone features of copper deficiency include subperiosteal new bone formation. Non-bone features include neutropenia, oedema, anaemia and late apnoea. All of these features can occur in preterm neonates for several different reasons, although neutropenia seems more specific for copper deficiency. It is difficult to be certain in the cases reported that improvement in rickets resulted from copper treatment, given the rapid healing which is known to occur in MBD of prematurity.

In a number of infants with bone disease ascribed to copper deficiency, blood copper concentrations lie within the 95% confidence interval for the population. In a group of 17 preterm neonates with fractures or rickets there was no reduction in blood copper concentration compared with those neonates without fractures. Additionally, serum copper estimation may not be the best way of assessing copper status, because reductions in red blood cell superoxide dismutase (a copper requiring enzyme) can occur in the presence of unchanged copper concentrations. The exact association between copper deficiency and MBD remains uncertain, although the presence of neutropenia may be a useful indicator.

Prevention of MBD

FORMULA FEEDING

If a preterm formula is tolerated overt MBD is unlikely. Preterm formulas in use in the United Kingdom contain between 17.5 and 27.5 mmol/l of calcium and 13.2 and 20.3 mmol/l of phosphorus. Even at these concentrations in utero accretion may not be achieved, perhaps because of mineral precipitation in milk.

Despite the original report, it has not been convincingly shown that in utero rates of bone mineral accretion can be achieved with such formulas. Although theoretically sound, such an approach is probably unnecessary given the rapid catchup in bone mineralisation, fall in alkaline phosphatase activity, and improved phosphorus concentration which occur after 40 weeks of conception and through early infancy. The catchup in bone mineralisation has been expressed in terms of forearm bone mineral content (BMC mg/cm) and in terms of whole body BMC. Sparse data on lumbar spinal bone mineral density (BMD mg/cm) also suggest rapid catchup to values in infants born at full term. Whether full catchup in BMD occurs in most infants remains to be established.

Pohlandt and Hillman et al. have suggested that in utero mineral accretion can only be achieved by using individually monitored supplementation with calcium and phosphorus, because of the natural interindividual variation in the processes of mineral absorption. Neonates who received doses adequate enough to permit simultaneous excretion of calcium (>1.2 mmol/l) and phosphorus (>0.4 mmol/l) in more than half of urine specimens, achieved such levels of mineral accretion. Given the complicated nature of this approach and without good evidence of long term benefits, it does not seem suited to routine clinical practice. Additionally, balance studies are only snapshots of net mineral absorption, with little information about day to day variability in mineral absorption in neonates.

In summary, modest mineral augmentation prevents overt MBD. Given the rapid catchup in bone mineralisation which occurs in the first year, and given that its effectiveness has not been conclusively shown, attempting to match in utero bone mineral accretion may not be necessary.

HUMAN MILK

In preterm neonates with nutritional hypophosphataemic rickets and fed with human milk, case reports show biochemical and radiological improvement in established MBD with phosphate supplementation at 0.81 mmol/kg/day. Supplementation of human milk with 1.61 mmol/day of phosphorus abolishes rickets, compared with an incidence of 42% in a control population. Fortification of human milk has been undertaken using a variety of proprietary and inhouse fortifiers, based on combinations of skimmed milk and calcium and phosphorus supplements. Fortification results in improved bone mineralisation, improved phosphate status, and reduced alkaline phosphatase activity. One study has suggested that powder fortification results in better bone mineralisation than that from liquid fortifier, perhaps related to the replacement of lactose with glucose polymer; lactose is felt to enhance dietary calcium absorption. Proprietary fortifiers in the United Kingdom are available as powders.
PARENTERAL NUTRITION

Enhanced calcium and phosphorus content of parenteral nutrition solutions reduces the risk and severity of MBD. Standard solutions contain up to 1 mmol/kg/day of both calcium and phosphorus. Enhancement to 1-9 mmol/kg/day calcium and 2-4 mmol/kg/day of phosphorus is associated with a reduction in the incidence of hypophosphataemia, fewer x-ray abnormalities, and improved bone mineralisation.34 35 It has been calculated that to match in utero retention, 3 mmol/kg/day of calcium and 2-8 mmol/kg/day of phosphorus are required.36 This molar ratio, slightly in excess of 1, is generally considered to allow the best retention of calcium and phosphorus. The aim of treatment should be to keep the blood phosphorus concentration above 1-2 mmol/l.

To enhance parenteral nutrition solutions requires careful discussion with the pharmacy department as the solubility of calcium and phosphorus depends on other components within the solutions, the order in which they are combined, and the ambient temperature.

One way around this problem is to use organic phosphorus salts which do not precipitate with calcium, which are stable in solution37 and achieve equivalent retentions to standard salts in similar doses.38 Results of studies are awaited and must include assessment of urinary calcium excretion and the incidence of nephrocalcinosis. Hypercalcaemia and nephrocalcinosis are associated with the use of parenteral nutrition in ill preterm neonates, and increased parenteral administration of calcium and phosphorus may increase the risk of these problems.

Vitamin D intakes of 30 IU/kg/day maintain adequate vitamin D status in parenterally nourished babies, as the main action of vitamin D is on gut absorption of calcium. Excess vitamin D is theoretically harmful as, in the presence of a low calcium intake, it may cause negative calcium balance by increasing bone demineralisation.39

FORMULA FEEDING

Nutrient enriched follow-on formulas have been developed for use in preterm neonates who have reached the upper weight limit for hospital preterm formulas. In addition to improved growth assessed by weight gain, the higher mineral content of the milk (17-5 mmol/l calcium and 11-3 mmol/l phosphorus) resulted in improved peripheral skeletal bone mineral content three months after discharge, the same difference persisting nine months after discharge.43 This suggests, as above,41 that the most important period of skeletal mineralisation occurs immediately after hospital discharge, when the infant may be developing increased vitamin D sensitivity. A short period of dietary mineral enhancement, say three months of an enriched formula, may be adequate in maximising bone mineral acquisition. In this study the control formula had a phosphorus and calcium content towards the lower end of the range used for full term milks, and had another milk been used for the controls, the difference in BMC may have been less striking.

After discharge

HUMAN MILK FEEDS

Two studies have been conducted of breast feeding continued after discharge in preterm neonates, who had all been fed human milk with fortifier in the neonatal nursery. Both showed evidence of impaired mineralisation relative to formula fed infants. Blood phosphorus concentration was lower and serum alkaline phosphatase activity was higher throughout the first year of life.40 41 This, despite the ameliorating effect of a more varied diet with weaning.

Forearm bone mineral content was also lower at 1 year of age in human milk fed than in formula fed infants.41 The deficit in bone mineral content is fully established by 25 weeks of age, after which it remains relatively unchanged. This suggests that a relatively brief period of dietary mineral supplementation after discharge will prevent it. Calcium and phosphorus supplementation for breast fed infants during this period reduced hypophosphataemia from about 50% to 10%, and may be a useful strategy in enhancing bone mineral acquisition.42

Treatment of established MBD

Treatment is undertaken on an empirical basis. A logical approach is to consider the individual nutrients discussed above. If a preterm formula, follow-on preterm formula, or fortified human milk are used, mineral insufficiency is unlikely. Phosphorus concentration should be checked and if hypophosphataemia (serum phosphorus concentration <1-2 mmol/l) or a high (>95%) tubular reabsorption of phosphorus are observed, phosphorus supplementation, starting at 1-8 mmol/day should be started.9 If such a situation has resulted during parenteral nutrition, check that phosphorus intake has been maximised and if it has consider oral phosphate supplementation. There is no requirement to increase the total daily dose of vitamin D above 1000 IU/day, although in an infant with liver disease vitamin D status may need to be assessed.

The peak time for the appearance of rickets and fractures is around 36 to 40 weeks after conception. MBD at this stage reflects earlier nutritional compromise, as the preterm neonate is usually receiving adequate nutrition. In this situation further dietary changes may well be unnecessary.

Because the production of hydroxyapatite (bone mineral) produces metabolic acid and because preterm neonates are frequently acidicotic, metabolic acidosis can be ameliorated by using phosphorus compounds which contain the smallest molar ratio of hydrogen ion.


Nutritional aspects of metabolic bone disease in the newborn.

S. Ryan

doi: 10.1136/fn.74.2.F145